SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
sc-12-0823_sm_CONSORT.pdf61KSupplementary Data
sc-12-0823_sm_SuppL_Infor.pdf123KSupplementary Data
sc-12-0823_sm_supplFigure1.tif621KSupporting Information Figure 1. Cyclosporine levels during four weeks of immunosuppression in pUCB group Horizontal bars and shaded area denote median values and the target range of level control (100 to 200 ng/mL), respectively. pUCB group received umbilical cord blood potentiated with rhEPO and rehabilitation
sc-12-0823_sm_supplFigure2.tif486KSupporting Information Figure 2. Changes in hemoglobin (A) and erythropoietin (B) levels during the study period of six months According to the protocol, hemoglobin level was monitored at 2 weeks, 3 weeks and 4 weeks after recombinant human erythropoietin (rhEPO) administration, and rhEPO was discontinued, when hemoglobin level reached 15g/dL. Bars represent SE. pUCB group received umbilical cord blood potentiated with recombinant human erythropoietin and rehabilitation; EPO group received recombinant human erythropoietin and rehabilitation; Control group received rehabilitation only.
sc-12-0823_sm_supplFigure3.pdf238KSupporting Information Figure 3. Baseline differences of glucose metabolism activity with 18F-FDG PET in three groups from paired comparisons (p-value < 0.05) Red colored areas indicate higher glucose metabolism in the later group, and blue colored areas represent lower glucose metabolism in the former group. pUCB group received umbilical cord blood potentiated with recombinant human erythropoietin and rehabilitation; EPO group received recombinant human erythropoietin and rehabilitation; Control group received rehabilitation only.
sc-12-0823_sm_supplFigure4.tif572KSupporting Information Figure 4. Comparing changes in fractional anisotropy (FA) from bilateral posterior lower pons, representing spinothalamic tract, during the period from baseline to 6 months post-treatment between three groups; pUCB group (n = 30), EPO group (n = 31), and Control group (n = 29) Bars represent 95% CI. pUCB group received umbilical cord blood potentiated with recombinant human erythropoietin and rehabilitation; EPO group received recombinant human erythropoietin and rehabilitation; Control group received rehabilitation only. p-values are reported for difference between two groups in FA changes, based on post-hoc analysis after ANOVA test.
sc-12-0823_sm_supplTable1.pdf83KSupplementary Table 1
sc-12-0823_sm_supplTable2.pdf91KSupplementary Table 2
sc-12-0823_sm_supplTable3.pdf90KSupplementary Table 3
sc-12-0823_sm_supplTable4.pdf81KSupplementary Table 4
sc-12-0823_sm_supplTable5.pdf84KSupplementary Table 5
sc-12-0823_sm_supplTable6.pdf88KSupplementary Table 6
sc-12-0823_sm_supplTable7.pdf85KSupplementary Table 7
sc-12-0823_sm_supplTable8.pdf85KSupplementary Table 8
sc-12-0823_sm_supplTable9.pdf85KSupplementary Table 9
sc-12-0823_sm_supplTable10.pdf85KSupplementary Table 10
sc-12-0823_sm_supplTable11.pdf85KSupplementary Table 11
sc-12-0823_sm_supplTable12.pdf90KSupplementary Table 12
sc-12-0823_sm_supplTable13-A.pdf82KSupplementary Table 13A
sc-12-0823_sm_supplTable13-B.pdf82KSupplementary Table 13B

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.